Posted by Michael Wonder on 12 Mar 2020
US FDA grants fast track designation to Jardiance for the treatment of chronic kidney disease
12 March 2020 - FDA fast track designation is for the investigation of potential new therapies that treat serious conditions and fulfil an unmet medical need.
The U.S. FDA has granted fast track designation for the investigation of Jardiance (empagliflozin) to reduce the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease, Boehringer Ingelheim and Eli Lilly announced.
This fast track designation for Jardiance underscores the urgent need for additional treatment options for the over 30 million Americans living with chronic kidney disease, many of whom are at risk of progressing to end-stage kidney disease.
